TITLE

Usefulness of gastric cancer screening using the serum pepsinogen test method

AUTHOR(S)
Miki, Kazumasa; Morita, Masuo; Sasajima, Masahiko; Hoshina, Reiko; Kanda, Eiko; Urita, Yoshihisa
PUB. DATE
April 2003
SOURCE
American Journal of Gastroenterology;Apr2003, Vol. 98 Issue 4, p735
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
: ObjectiveThe measurement of serum pepsinogen has recently gained attention as a candidate for a new screening test for gastric cancer. This method is particularly attractive given its lower cost and simplicity to administer relative to photofluorography. To compare the accuracy between the two screening methods, and to elucidate the usefulness of the serum pepsinogen test method, we performed this study.: MethodsMass screening for gastric cancer was performed using both the x-ray and pepsinogen test methods simultaneously on 286 company employees. The number of tests conducted was 5567 in total. The mean age was 48 yr in both men and women. Informed consent was taken individually. Fasting blood samples were collected, and measurement of the serum pepsinogen concentration was carried out by immunoradiometric assay.: ResultsThe percentage of those screened, who needed further examination was 11.7% for the x-ray method and 23.6% for the pepsinogen test method. The percentage of those who required further investigation, as the second step of screening, using endoscopy, was 55.4% for the x-ray method and 51.9% for the pepsinogen test method, respectively. Ten gastric cancers were detected in total. The incidence was 0.05% in the x-ray method and 0.18% in the pepsinogen test method. The rate of early gastric cancer to advanced gastric cancer was 9 to 1, that is, 90% were in the early stages. The positive predictive value was 0.8% in the x-ray method and 1.4% in the pepsinogen test method.: ConclusionsThe pepsinogen test method can be used as a screening test for high-risk subjects with atrophic gastritis, rather than as a tool for cancer itself. Systemic endoscopic surveillance of this group is also useful.
ACCESSION #
9658085

 

Related Articles

  • Serum Pepsinogen I as a Predictor of Stomach Cancer. Nomura, Abraham M. Y.; Stemmermann, Grant N.; Samloff, I. Michael // Annals of Internal Medicine;Oct80, Vol. 93 Issue 4, p537 

    Presents a study which investigated the hypothesis that a low serum pepsinogen I level might also be subclinical marker of increased susceptibility for gastric cancer. Correlationn between intestinal metaplasia and intestinal-mixed-other types of gastric cancer; Methods used; Discussion,

  • The new modified ABCD method for gastric neoplasm screening. Park, Chan; Kim, Eun; Jung, Da; Chung, Hyunsoo; Park, Jun; Shin, Sung; Lee, Sang; Lee, Yong // Gastric Cancer;Jan2016, Vol. 19 Issue 1, p128 

    Background: The ABCD screening method was developed for risk stratification of gastric cancer. It is unclear whether the ABCD method can predict the risk of gastric neoplasms, including gastric adenomas, as observed for gastric cancer. We aimed to devise a modified ABCD method for predicting...

  • Validity of Serum Pepsinogen I/II Ratio for the Diagnosis of Gastric Epithelial Dysplasia and Intestinal Metaplasia during the Follow-Up of Patients at Risk for Intestinal-Type Gastric Adenocarcinoma. Dinis-Ribeiro, Mário; Da Costa-Pereira, Altamiro; Lopes, Carlos; Barbosa, Joana; Guilherme, Mateus; Moreira-Dias, Luís; Lomba-Viana, Helena; Silva, Rui; Abreu, Nuno; Lomba-Viana, Rafael // Neoplasia;Sep/Oct2004, Vol. 6 Issue 5, p449 

    A cohort of individuals (n = 136) with lesions as severe as atrophic chronic gastritis (ACG) was cross-sectionally evaluated for the validity assessment of pepsinogen I (PGI) and pepsinogen II (PGII) serum levels for the diagnosis of intestinal metaplasia (IM) and gastric dysplasia. PGI/PGII...

  • Changes in evaluation of the pepsinogen test result following Helicobacter pylori eradication therapy in Japan. Kawai, T.; Miki, K.; Ichinose, M.; Kenji, Y.; Miyazaki, I.; Kawakami, K.; Kataoka, M.; Yamagishi, T.; Sofuni, A.; Itoi, T.; Moriyasu, F.; Takagi, Y.; Aoki, T.; Matsubayashi, J.; Mukai, K. // Inflammopharmacology;Feb2007, Vol. 15 Issue 1, p31 

    The pepsinogen (PG) test result is used in Japan for screening for gastric cancer. In this study, we investigated the changes in evaluation of the PG test result following H. pylori eradication. The subjects were 120 consecutive H. pylori-positive patients with upper gastrointestinal symptoms....

  • Low Serum Levels of Pepsinogen and Gastrin 17 Are Predictive of Extensive Gastric Atrophy with High-Risk of Early Gastric Cancer. Kikuchi, Ryousuke; Abe, Yasuhiko; Iijima, Katsunori; Koike, Tomoyuki; Ara, Nobuyuki; Uno, Kaname; Asanuma, Kiyotaka; Asano, Naoki; Imatani, Akira; Shimosegawa, Tooru // Tohoku Journal of Experimental Medicine;Jan2011, Vol. 223 Issue 1, p35 

    Atrophic gastritis (AG) is a well-recognized high-risk condition for developing gastric cancer (GC). Gastrin 17 (G17), a hormone secreted from antral G cells, regulates gastric acid secretion, and its serum level is a possible indicator of antral atrophy. Serum pepsinogen is well established as...

  • The co-expression of functional gastric proteins in dynamic gastric diseases and its clinical significance. Qian Xu; Li-ping Sun; Ben-gang Wang; Jing-wei Liu; Ping Li; Cai-yun He; Yuan Yuan // BMC Clinical Pathology; 

    Background: Pepsinogen C (PGC) and mucin1 (MUC1) are important physiologically functional gastric proteins; Mucin2 (MUC2) is an "ectopic" functional protein in intestinal metaplasia of gastric mucosa. We analyzed the co-expression of the above-mentioned three proteins in dynamic gastric diseases...

  • Predicting the development of gastric cancer from combining Helicobacter pylon antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Watabe, H.; Mitsushima, T.; Yamaji, Y.; Okamoto, M.; Wada, R.; Kokubo, T.; Doi, H.; Yoshida, H.; Kawabe, T.; Omata, M. // Gut;Jun2005, Vol. 54 Issue 6, p764 

    Background and aim: Helicobacter pylon infection and gastric atrophy are both risk factors for gastric cancer. We aimed to elucidate the natural history of gastric cancer development according to H pylon infection and gastric atrophy status. Subjects and methods: A total of 9293 participants in...

  • The Serum Pepsinogen Test as a Predictor of Gastric Cancer. Oishi, Yoshinori; Kiyohara, Yutaka; Kubo, Michiaki; Tanaka, Keiichi; Tanizaki, Yumihiro; Ninomiya, Toshiharu; Doi, Yasufumi; Shikata, Kentaro; Yonemoto, Koji; Shirota, Tomoko; Matsumoto, Takayuki; Iida, Mitsuo // American Journal of Epidemiology;Apr2006, Vol. 163 Issue 7, p629 

    The authors examined whether a serum pepsinogen test (SPT) based on the combination of the serum pepsinogen I level and pepsinogen I/II ratio is a good predictor of gastric cancer occurrence in a general Japanese population. A total of 2,446 subjects aged ≥40 years were classified into...

  • Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Mizuno, Shigeto; Kobayashi, Masao; Tomita, Shohken; Miki, Ikuya; Masuda, Atsuhiro; Onoyama, Mitsuko; Habu, Yasuki; Inokuchi, Hideto; Watanabe, Yoshiyuki // Gastric Cancer;Oct2009, Vol. 12 Issue 3, p158 

    Serum pepsinogen (PG) measurement has been used for gastric cancer screening since the 1990s. However, there are no reports comparing the screening validity of the PG test method with that of conventional X-ray examination directly in the same population, using a follow-up study. From April 2000...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics